Warfarin Patient Self-management Implementation in the US Healthcare System

Last updated: May 6, 2024
Sponsor: University of Utah
Overall Status: Active - Recruiting

Phase

N/A

Condition

Venous Thromboembolism

Blood Clots

Venous Thrombosis

Treatment

Usual care provided by anticoagulation providers

Patient self-management

Clinical Study ID

NCT04766216
IRB_00141141
  • Ages > 18
  • All Genders

Study Summary

In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinic-directed warfarin management. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • At least 18 years of age treated with warfarin for any indication for at least 9months prior to enrollment
  • Demonstrate the willingness and ability to test their own INR using a home INRmonitoring device or have same-day access to clinic-derived INR results (e.g., viaelectronic medical record secure messaging)
  • Willing to make independent decisions about warfarin dosing based on INR results
  • Able to perform INR tests at least every 2 weeks
  • Currently have and willing to maintain internet access for the duration of the studyin order to complete online data collection forms
  • Have an anticipated duration of warfarin therapy of at least 6 months

Exclusion

Exclusion Criteria:

  • Goal INR range other than 2.0-3.0 or 2.5-3.5
  • Known poor adherence to warfarin therapy
  • Non-English speaking
  • Inability or refusal to provide written informed consent

Study Design

Total Participants: 150
Treatment Group(s): 2
Primary Treatment: Usual care provided by anticoagulation providers
Phase:
Study Start date:
March 15, 2023
Estimated Completion Date:
April 30, 2025

Study Description

In the US, patients receiving warfarin therapy are rarely allowed to engage in patient self-management (PSM) which is less burdensome, less expensive, and safer than standard clinician-directed warfarin management. National and international evidence-based guideline panels strongly recommend PSM over other warfarin management methods for appropriate patients because it improves INR control, cuts risk of thrombosis and death by half without increasing bleeding risk, and increases patient satisfaction and quality of life. The reasons behind PSM underutilization in US settings have not been systematically assessed and validated. We will address this knowledge gap and provide foundational information for increasing PSM utilization within the US healthcare system. Our Aim 1 will assess and validate barriers and facilitators to PSM and evaluate their applicability to the US healthcare system; Aim 2 will develop and test PSM implementation strategies in US ambulatory care sites using rapid-cycle research methodology; and Aim 3 will assess implementation (feasibility, fidelity, adoption), clinical (effectiveness, safety, equity, patient-centeredness), and end-user (satisfaction) outcomes. The long-term objective of our application is to improve the safety of ambulatory warfarin therapy through increasing the implementation of PSM. Our research proposal is guided by an implementation science logic model that incorporates well-known implementation science frameworks to support the specific aims. Qualitative data collection and analysis for Aim 1 will be organized using the Consolidated Framework for Implementation Research (CFIR) a determinant framework that identifies five domains influencing implementation: Intervention, Inner Setting, Outer Setting, Individuals, and the Implementation Process. Constructs within each domain provide guidance on factors to identify and measure as potential implementation barriers or facilitators. PSM implementation activities in Aim 2 will be guided by the Quality Implementation Framework (QIF), which identifies the critical implementation process steps and specific actions related to these steps that can be utilized to achieve quality PSM implementation. Implementation strategies will be supported by the rapid-cycle research framework developed by the AHRQ Practice Based Research Network. Implementation outcomes in Aim 3 will be structured using the well-known Reach, Efficacy, Adoption, Implementation, Maintenance (RE-AIM) framework. We will utilize a type III hybrid research design to test PSM implementation strategies while observing/gathering information on PSM-related clinical and economic outcomes.

Connect with a study center

  • VA Loma Linda Healthcare System

    Loma Linda, California 92357
    United States

    Active - Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts 02115
    United States

    Completed

  • University of Michigan

    Ann Arbor, Michigan 48109
    United States

    Completed

  • University of Utah Thrombosis Center

    Salt Lake City, Utah 84112
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.